1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin.
2019;69:7–34.
2. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet.
2020;395:2008–20.
3. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin
DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:439–57.
4. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson
CM, et al. DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J Clin Oncol.
2009;27:1806–13.
5. Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke
HF. Prognostic factors and sites of metastasis in unresectable locally
advanced pancreatic cancer. Cancer Med. 2015;4:1171–7.
6. Burnet NG, Mee T, Gaito S, Kirkby NF, Aitkenhead AH, Anandadas
CN, et al. Estimating the percentage of patients who might benefit
from proton beam therapy instead of X-ray radiotherapy. Br J Radiol.
2022;95:20211175.
7. Gaito S, Marvaso G, Ortiz R, Crellin A, Aznar MC, Indelicato DJ, et al. Proton
beam therapy in the oligometastatic/oligorecurrent setting: Is there a
role? A literature review. Cancers (Basel). 2023;15:2489.
8. Greco C, Wolden S. Current status of radiotherapy with proton and light
ion beams. Cancer. 2007;109:1227–38.
9. Gaito S, Hwang EJ, France A, Aznar MC, Burnet N, Crellin A, et al. Outcomes of patients treated in the UK proton overseas programme: central nervous system group. Clin Oncol (R Coll Radiol). 2023;35:283–91.
10. Hwang E, Gaito S, France A, Crellin AM, Thwaites DI, Ahern V, et al.
Outcomes of patients treated in the UK proton overseas programme:
non-central nervous system group. Clin Oncol (R Coll Radiol).
2023;35:292–300.
11. Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, et al. A
phase I/II study of gemcitabine-concurrent proton radiotherapy for
locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012;103:25–31.
12. Sachsman S, Nichols RC, Morris CG, Zaiden R, Johnson EA, Awad
Z, et al. Proton therapy and concomitant capecitabine for nonmetastatic unresectable pancreatic adenocarcinoma. Int J Part Ther.
2014;1:692–701.
13. Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K,
et al. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol. 2019;136:37–43.
Ami et al. Radiation Oncology
(2023) 18:131
14. Kawashiro S, Yamada S, Okamoto M, Ohno T, Nakano T, Shinoto M,
et al. Multi-institutional study of carbon-ion radiotherapy for locally
advanced pancreatic cancer: Japan Carbon-ion Radiation Oncology
Study Group (J-CROS) study 1403 pancreas. Int J Radiat Oncol Biol
Phys. 2018;101:1212–21.
15. Ogura Y, Terashima K, Nanno Y, Park S, Suga M, Takahashi D, et al. Factors associated with long-term survival in gemcitabine-concurrent
proton radiotherapy for non-metastatic locally advanced pancreatic
cancer: a single-center retrospective study. Radiat Oncol. 2022;17:32.
16. Kagawa K, Murakami M, Hishikawa Y, Abe M, Akagi T, Yanou T, et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo
Ion Beam Medical Center. Int J Radiat Oncol Biol Phys. 2002;54:928–38.
17. Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al.
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet
Gastroenterol Hepatol. 2020;5:285–94.
18. Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and
patient-level meta-analysis. Lancet Oncol. 2016;17:801–10.
19. Takeda T, Sasaki T, Mie T, Furukawa T, Yamada Y, Kasuga A, et al. The prognostic impact of tumour location and first-line chemotherapy regimen in
locally advanced pancreatic cancer. Jpn J Clin Oncol. 2021;51:728–36.
20. Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, et al. Role of
FOLFIRINOX and chemoradiotherapy in locally advanced and borderline
resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J
Cancer. 2021;124:1941–8.
21. Takada R, Ikezawa K, Daiku K, Maeda S, Abe Y, Urabe M, et al. The survival
benefit of chemoradiotherapy following induction chemotherapy with
gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Cancers (Basel). 2021;13:4733.
22. Shi Z, Yang J, Kong W, Qiu X, Lu C, Liu J, et al. Use of nab-paclitaxel plus
gemcitabine followed by hypofractionated tomotherapy with simultaneous integrated boost in patients with locally advanced pancreatic cancer.
Front Oncol. 2022;12:782730.
23. Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, et al. A phase II randomised trial
of induction chemotherapy followed by concurrent chemoradiotherapy
in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology
Group T2212 study. Br J Cancer. 2022;126:1018–26.
24. Sofue K, Tsurusaki M, Murakami T, Onoe S, Tokue H, Shibamoto K, et al.
Does Gadoxetic acid-enhanced 3.0T MRI in addition to 64-detectorrow contrast-enhanced CT provide better diagnostic performance and
change the therapeutic strategy for the preoperative evaluation of
colorectal liver metastases? Eur Radiol. 2014;24:2532–9.
25. Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, et al.
Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23:750–5.
26. Satoi S, Yanagimoto H, Yamamoto T, Toyokawa H, Hirooka S, Yamaki S,
et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World
J Surg Oncol. 2016;14:14.
27. Suker M, Koerkamp BG, Coene PP, van der Harst E, Bonsing BA, Vahrmeijer
AL, et al. Yield of staging laparoscopy before treatment of locally
advanced pancreatic cancer to detect occult metastases. Eur J Surg
Oncol. 2019;45:1906–11.
28. Takadate T, Morikawa T, Ishida M, Aoki S, Hata T, Iseki M, et al. Staging
laparoscopy is mandatory for the treatment of pancreatic cancer to avoid
missing radiologically negative metastases. Surg Today. 2021;51:686–94.
29. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J
Radiat Oncol Biol Phys. 1996;34:867–72.
30. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine
alone in patients with locally advanced and metastatic pancreatic cancer
in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–8.
31. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder
E, et al. Induction gemcitabine and stereotactic body radiotherapy for
locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol
Phys. 2011;81:e615–22.
32. Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, et al. Phase II clinical
trial of induction chemotherapy with fixed dose rate gemcitabine and
Page 10 of 10
33. 34. 35. 36. 37. 38. 39. cisplatin followed by concurrent chemoradiotherapy with capecitabine
for locally advanced pancreatic cancer. Cancer Chemother Pharmacol.
2012;70:381–9.
Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al.
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally
advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase
2 trial. Lancet Oncol. 2013;14:317–26.
Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 2020;10:245.
Chung SY, Chang JS, Lee BM, Kim KH, Lee KJ, Seong J. Dose escalation
in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol. 2017;123:438–45.
Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally
advanced pancreatic cancer: techniques and results. Radiat Oncol.
2019;14:95.
Abi Jaoude J, Kouzy R, Nguyen ND, Lin D, Noticewala SS, Ludmir EB,
et al. Radiation therapy for patients with locally advanced pancreatic
cancer: evolving techniques and treatment strategies. Curr Probl Cancer.
2020;44:100607.
Lee D, Komatsu S, Terashima K, Toyama H, Matsuo Y, Takahashi D, et al.
Surgical spacer placement for proton radiotherapy in locally advanced
pancreatic body and tail cancers: initial clinical results. Radiat Oncol.
2021;16:3.
Sasaki R, Demizu Y, Yamashita T, Komatsu S, Akasaka H, Miyawaki D, et al.
First-in-human phase 1 study of a nonwoven fabric bioabsorbable spacer
for particle therapy: space-making particle therapy (SMPT). Adv Radiat
Oncol. 2019;4:729–37.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ready to submit your research ? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
...
論文の公開元へ
